Prostate carcinoma and radiation therapy: Therapeutic treatment resistance and strategies for targeted therapeutic intervention

Expert Review of Anticancer Therapy

Volumn 8, Issue 6, 2008, Pages 967-974

  FitzGerald, T J ^a   Wang, Tao ^a   Goel, Hira Lai ^a   Huang, Jiayi ^a   Stein, Gary ^a   Lian, Jane ^a   Davis, Roger J ^a   Doxsey, Steven ^a   Balaji, K C ^a   Aronowitz, Jesse ^a   Languino, Lucia R ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Casodex ; IGF IR; Integrin; Prostate cancer; Radiation therapy

Indexed keywords

ALPHA6 INTEGRIN; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; BICALUTAMIDE; DOCETAXEL; INTEGRIN; PACLITAXEL; SOMATOMEDIN C RECEPTOR; STRESS ACTIVATED PROTEIN KINASE; TAXANE DERIVATIVE; TRANSCRIPTION FACTOR RUNX2; PROSTATE SPECIFIC ANTIGEN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BRACHYTHERAPY; CANCER HORMONE THERAPY; CANCER INHIBITION; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RESISTANCE; CELL ADHESION; CLINICAL TRIAL; DNA DAMAGE; DRUG MECHANISM; DRUG RECEPTOR BINDING; HUMAN; IONIZING RADIATION; NONHUMAN; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATE CARCINOMA; RADIOSENSITIVITY; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR RECURRENCE; ADENOCARCINOMA; BLOOD; CANCER STAGING; MALE; PATHOLOGY; PROSTATE TUMOR; RADIATION DOSE; RISK FACTOR; TREATMENT OUTCOME;

ADENOCARCINOMA; HUMANS; MALE; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIATION TOLERANCE; RISK FACTORS; TREATMENT OUTCOME;

EID: 47249098017     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.8.6.967     Document Type: Review

References (40)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J. Clin. 58(2), 71-96 (2008).
2. FitzGerald TJ, Simon E, Meyer J. Prostate carcinoma: Opportunities for translational research. J. Cell Biochem. 91(3), 433-442 (2004).
3. Radiology for the Radiologist. Hall E, Giacca AJ (Eds). Lippincott, Williams & Wilkins, Columbia University, NY, USA (2006).
4. Ahmed MM. Regulation of radiation-induced apoptosis by early growth response-1 gene in solid tumors. Curr. Cancer Drug Targets, 4(1), 43-52 (2004).
5. Calaf GM, Hei TK. Ionizing radiation induces alterations in cellular proliteration and c-myc, c-jun and c-fos protein expression in breast epithelial cells. Int. J. Oncol. 25(6), 1859-1866 (2004).
6. Hehlgans S, Haase M, Cordes N. Signalling via integrins: implications for cell survival and anticancer strategies. Biochim. Biophys. Acta 1775(1), 163-180 (2007).
7. Cordes N, Blaese MA, Plasswilm L, Rodemann HP, Van Beuningen D. Fibronectin and laminin increase resistance to ionizing radiation and the cytotoxic drug Ukrain in human tumour and normal cells in vitro. Int. J. Radiat. Biol. 79(9), 709-720 (2003).
8. Onoda JM, Piechocki MP, Honn KV. Radiation-induced increase in expression of the αIIb β3 integrin in melanoma cells: effects on metastatic potential. Radiat. Res. 1300), 281-288 (1992).
9. 3 integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. Cancer Res. 62(15), 4263-4272 (2002).
10. Cao Q, Cai W, Li T et al. Combination of integrin siRNA and irradiation for breast cancer therapy. Biochem. Biophys. Res. Commun. 351(3), 726-732 (2006).
11. Cordes N, Seidler J, Durzok R, Geinitz H, Brakebusch C. β1-integrin-mediated signaling essentially contributes to cell survival after radiation-induced genotoxic injury. Oncogene 25(9), 1378-1390 (2006).
12. 1 integrin expxession as a prediction marker for radiotherapy in early glottic carcinoma. Laryngoscope 116(7), 1228-1231 (2006).
13. 6 integrin in cervical squamous cell carcinoma is a prognostic factor for decreased survival. J. Pathol. 212(3), 316-324 (2007).
14. Simon EL, Goel HL, Teider N, Wang T, Languino LR, Fitzgerald TJ. High dose fractionated ionizing radiation inhibits prostate cancer cell adhesion and β1 integrin expression. Prostate 64(1), 83-91 (2005).
15. 3 integrin promotes resistance of prostate cancer cells to ionizing radiation. Int. J. Rad. Onc. Biol. Phys. 69(3 Suppl.), S611 (2007).
16. Altieri DC. The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol. Med. 7(12), 542-547 (2001).
17. Masiello D, Cheng S, Bubley GJ, Lu ML, Balk SP. Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor. J. Biol. Chem. 277(29), 26321-26326 (2002).
18. Alavian MR, Wang T, Goel HL, Languino LR, Fitzgerald TJ. Bicalutamide inhibits androgen promotion of prostate cancer cell adhesion when exposed to ionizing radiation. Presented at: 53rd Annual Meeting of the Radiation Research Society. PA, USA, 5-8 November 2006.
19. Valentinis B, Baserga R. IGF-I receptor signalling in transformation and differentiation. Mol. Pathol. 54(3), 133-137 (2001).
20. Kaplan PJ, Mohan S, Cohen P, Foster BA, Greenberg NM. The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model. Cancer Res. 59(9), 2203-2209 (1999).
21. Werner H, LeRoith D. The role of the insulin-like growth factor system in human cancer. Adv. Cancer Res. 68, 183-223 (1996).
22. Watanabe H, Miura M, Sasaki T. Differential effects of the insulin-like growth factor I receptor on radiosensitivity and spontaneous necrosis formation of human glioblastoma cells grown in multicellular spheroids. Exp. Cell Res., 25(1), 99-111 (1999).
23. Yu D, Shibuya H, Miura M. Roles of the insulin-like growth factor I receptor C-terminus in cellular radioresistance. Biochem. Biophys. Res. Commun. 311 (1), 174-178 (2003).
24. Turner BC, Haffty BG, Narayanan L et al. Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res. 57(15), 3079-3083 (1997).
25. Allen GW, Saba C, Armstrong EA et al. Insulin-like growth factor-I receptor signaling blockade combined with radiation. Cancer Res. 67(3), 1155-1162 (2007).
26. Peretz S, Jensen R, Baserga R, Glazer PM. ATM-dependent expression of the insulin-like growth factor-I receptor in a pathway regulating radiation response. Proc. Natl Acad. Sci. USA 98(4), 1676-1681 (2001).
27. 1 integrins. J. Cell Biol. 166(3), 407-418 (2004).
28. Yu D, Watanabe H, Shibuya H, Miura M. Redundancy of radioresistant signaling pathways originating from insulin-like growth factor-I receptor. J. Biol. Chem. 278(9), 6702-6709 (2003).
29. Wang T, Languino LR, Fitzgerald TJ. Insulin-like growth factor type I receptor (IGF-IR) mediates radioresistance of DU-145 and PC3 human prostate cancer cells during ionizing radiation. Presented at: 52nd Annual Meeting of the Radiation Research Society (2005).
30. Weston CR, Davis RJ. The JNK signal transduction pathway. Curr. Opin. Cell Biol. 19(2), 142-149 (2007).
31. Almeida EA, Ilic D, Han Q et al. Matrix survival signaling. From fibronectin via focal adhesion kinase to c-jun nh(2)-terminal kinase. J. Cell Biol. 149(3), 741-754 (2000).
32. An J, Chervin AS, Nie A, Ducoff HS, Huang Z. Overcoming the radioresistance of prostate cancer cells with a novel Bcl-2 inhibitor. Oncogene 26(5), 652-661 (2007).
33. Su ZZ, Lebedeva IV, Sarkar D et al. Ionizing radiation enhances therapeutic activity of mda-7/IL-24: overcoming radiation- and mda-7/ IL-24-resistance in prostate cancer cells overexpressing the antiapoptotic proteins bcl-xL or bcl-2. Oncogene 25(16), 2339-2348 (2006).
34. Bowen C, Birrer M, Gelmann EP. Retinoblastoma protein-mediated apoptosis after γ-irradiation. J. Biol. Chem. 277(47), 44969-44979 (2002).
35. Blyth K, Cameron ER, Neil JC. The RUNX genes: gain or loss of function in cancer. Nat. Rev. 5(5), 376-387 (2005).
36. Zaidi SK, Pande S, Pratap J et al. Runx2 deficiency and defective subnuclear targeting bypass senescence to promote immortalization and tumorigenic potential. Proc. Natl Acad. Sci. USA 104(50), 19861-19866 (2007).
37. Young DW, Hassan MQ, Yang XQ et al. Mitotic retention of gene expression patterns by the cell fate-determining transcription factor Runx2. Proc. Natl Acad. Sci. USA 104(9), 3189-3194 (2007).
38. Young DW, Hassan MQ, Pratap J et al. Mitotic occupancy and lineage-specific transcriptional control of rRNA genes by Runx2. Nature 445(7126), 442-446 (2007).
39. Javed A, Barnes GL, Pratap J et al. Impaired intranuclear trafficking of Runx2 (AML3/CBFA1) transcription factors in breast cancer cells inhibits osteolysis in vivo. Proc. Natl Acad. Sci. USA 102(5), 1454-1459 (2005).
40. Pawar SC, Dougherty S, Pennington ME, et al. α6 integrin cleavage: sensitizing human prostate cancer to ionizing radiation. Int. J. Rad. Biol. 830 (11-12), 761-767 (2007).